Correction: Current status of human biomonitoring of beauvericin and enniatins - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction: Updated overview of human biomonitoring for beauvericin and enniatins

  • By

  • Gisela H. Degen

  • Anamarija Romac

  • November 13, 2026

Share

Clinical Scorecard: Correction: Updated overview of human biomonitoring for beauvericin and enniatins

At a Glance

CategoryDetail
ConditionCorrection notice for an article; the notice does not specify a condition.
Key MechanismsNot described in the correction notice.
Target PopulationNot specified in the correction notice.
Care SettingNot specified in the correction notice.

Key Highlights

  • The notice corrects a misspelling of first author Gisela H. Degen’s name; it appears as “Gsela H. Degen.”
  • In Table 2, the second-line data in the final column, headed “Kyei et al. 2026,” are reported as “9191.7%”; the correct entry is “91.7% > LOQ.”
  • A correction has been issued for the article.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          No patient population or prescribing data are provided.

          No treatment information is provided.

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            Correction: Current status of human biomonitoring of beauvericin and enniatins

            • by Gisela H. Degen, Anamarija Romac

            • November 13, 2026

            Related Content

            What Your Patients Need to Know for Medicare Open Enrollment

            The annual Medicare open enrollment period runs October 15 to December 7 this year, giving adults ages 65 and older the opportunity to review and possibly change their healthcare coverage.

            • by

            • November 5, 2026

            • 2 min
            WHO 2026 global TB report: Mortality misses 2025 target

            Global TB deaths fell 35% since 2015, well short of the targeted 75% reduction.

            Can CTCA prevent cardiac event after MI ruled out?

            In a randomized trial, additional imaging increased preventive treatment but did not significantly reduce subsequent myocardial infarction or cardiac mortality over 3 years.